Overview

Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Annick Desjardins
Treatments:
Bevacizumab
Camptothecin
Carboplatin
Irinotecan